7-octadecynoic acid

7-octadecynoic acid is a lipid of Fatty Acyls (FA) class.

Cross Reference

There are no associated biomedical information in the current reference collection.

Current reference collection contains 19785 references associated with 7-octadecynoic acid in LipidPedia. Due to lack of full text of references or no associated biomedical terms are recognized in our current text-mining method, we cannot extract any biomedical terms related to diseases, pathways, locations, functions, genes, lipids, and animal models from the associated reference collection.

Users can download the reference list at the bottom of this page and read the reference manually to find out biomedical information.


Here are additional resources we collected from PubChem and MeSH for 7-octadecynoic acid

Possible diseases from mapped MeSH terms on references

We collected disease MeSH terms mapped to the references associated with 7-octadecynoic acid

MeSH term MeSH ID Detail
Body Weight D001835 333 associated lipids
Lung Neoplasms D008175 171 associated lipids
Adenocarcinoma D000230 166 associated lipids
Colonic Neoplasms D003110 161 associated lipids
Carcinoma, Hepatocellular D006528 140 associated lipids
Prostatic Neoplasms D011471 126 associated lipids
Inflammation D007249 119 associated lipids
Hypertension D006973 115 associated lipids
Glioma D005910 112 associated lipids
Weight Gain D015430 101 associated lipids
Insulin Resistance D007333 99 associated lipids
Hypercholesterolemia D006937 91 associated lipids
Diabetes Mellitus D003920 90 associated lipids
Brain Ischemia D002545 89 associated lipids
Diabetes Mellitus, Type 2 D003924 87 associated lipids
Arteriosclerosis D001161 86 associated lipids
Diabetes Mellitus, Experimental D003921 85 associated lipids
Atherosclerosis D050197 85 associated lipids
Pancreatic Neoplasms D010190 77 associated lipids
Alzheimer Disease D000544 76 associated lipids
Leukemia D007938 74 associated lipids
Carcinoma, Non-Small-Cell Lung D002289 72 associated lipids
Coronary Disease D003327 70 associated lipids
Liver Cirrhosis D008103 67 associated lipids
Neuroblastoma D009447 66 associated lipids
Cystic Fibrosis D003550 65 associated lipids
Weight Loss D015431 56 associated lipids
Diabetes Mellitus, Type 1 D003922 56 associated lipids
Nerve Degeneration D009410 53 associated lipids
Kidney Failure, Chronic D007676 51 associated lipids
Osteosarcoma D012516 50 associated lipids
Coronary Artery Disease D003324 47 associated lipids
Metabolic Syndrome D024821 44 associated lipids
Lupus Erythematosus, Systemic D008180 43 associated lipids
Hypersensitivity, Delayed D006968 43 associated lipids
Hyperalgesia D006930 42 associated lipids
Arthritis D001168 41 associated lipids
Diabetic Nephropathies D003928 39 associated lipids
Neovascularization, Pathologic D009389 39 associated lipids
Heart Failure D006333 36 associated lipids
Spinal Cord Injuries D013119 34 associated lipids
Uremia D014511 33 associated lipids
Thyroid Neoplasms D013964 33 associated lipids
Ventricular Dysfunction, Left D018487 33 associated lipids
Hypertension, Pulmonary D006976 32 associated lipids
Diarrhea D003967 32 associated lipids
Hypothyroidism D007037 32 associated lipids
Obesity D009765 29 associated lipids
Endometriosis D004715 29 associated lipids
Kidney Diseases D007674 29 associated lipids
Ventricular Remodeling D020257 28 associated lipids
Autoimmune Diseases D001327 27 associated lipids
Mammary Neoplasms, Animal D015674 27 associated lipids
Hyperinsulinism D006946 27 associated lipids
Leukemia, Lymphocytic, Chronic, B-Cell D015451 25 associated lipids
Arthritis, Experimental D001169 24 associated lipids
Cardiovascular Diseases D002318 24 associated lipids
Genetic Predisposition to Disease D020022 24 associated lipids
Neoplasm Invasiveness D009361 23 associated lipids
Periodontitis D010518 22 associated lipids
Cachexia D002100 21 associated lipids
Myocardial Infarction D009203 21 associated lipids
Wounds and Injuries D014947 20 associated lipids
Diabetic Angiopathies D003925 20 associated lipids
HIV Infections D015658 20 associated lipids
Carcinoma, Ductal, Breast D018270 19 associated lipids
Albuminuria D000419 18 associated lipids
Carcinoma D002277 18 associated lipids
Brain Infarction D020520 17 associated lipids
Vascular Diseases D014652 16 associated lipids
Scleroderma, Systemic D012595 16 associated lipids
Celiac Disease D002446 16 associated lipids
Atrial Fibrillation D001281 16 associated lipids
Pulmonary Disease, Chronic Obstructive D029424 16 associated lipids
Synovitis D013585 15 associated lipids
Carotid Stenosis D016893 15 associated lipids
Periodontal Diseases D010510 15 associated lipids
Encephalitis D004660 15 associated lipids
HIV Seropositivity D006679 15 associated lipids
Stomatitis D013280 14 associated lipids
Polycystic Ovary Syndrome D011085 14 associated lipids
Angina, Unstable D000789 14 associated lipids
Osteoarthritis, Knee D020370 13 associated lipids
Multiple Myeloma D009101 13 associated lipids
Hypercalcemia D006934 13 associated lipids
Vitamin D Deficiency D014808 13 associated lipids
Polycythemia Vera D011087 13 associated lipids
Crohn Disease D003424 12 associated lipids
Familial Mediterranean Fever D010505 12 associated lipids
Hepatitis C, Chronic D019698 12 associated lipids
Osteoporosis D010024 12 associated lipids
Disease Susceptibility D004198 12 associated lipids
Hypocalcemia D006996 12 associated lipids
Sepsis D018805 11 associated lipids
Aortic Diseases D001018 11 associated lipids
Pregnancy Complications, Hematologic D011250 11 associated lipids
Acute Coronary Syndrome D054058 11 associated lipids
Venous Thrombosis D020246 11 associated lipids
Thinness D013851 11 associated lipids
Myocardial Ischemia D017202 11 associated lipids
Per page 10 20 50 100 | Total 298

All references with 7-octadecynoic acid

Download all related citations
Per page 10 20 50 100 | Total 4091
Authors Title Published Journal PubMed Link
Schinke T et al. Molecular determinants of arterial calcification. 1998 Ann. Med. pmid:9920355
Akatsu T et al. Osteoclastogenesis inhibitory factor exhibits hypocalcemic effects in normal mice and in hypercalcemic nude mice carrying tumors associated with humoral hypercalcemia of malignancy. 1998 Bone pmid:9855457
Murakami T et al. Transforming growth factor-beta1 increases mRNA levels of osteoclastogenesis inhibitory factor in osteoblastic/stromal cells and inhibits the survival of murine osteoclast-like cells. 1998 Biochem. Biophys. Res. Commun. pmid:9837778
Yun TJ et al. OPG/FDCR-1, a TNF receptor family member, is expressed in lymphoid cells and is up-regulated by ligating CD40. 1998 J. Immunol. pmid:9834095
Vidal NO et al. Osteoprotegerin mRNA is expressed in primary human osteoblast-like cells: down-regulation by glucocorticoids. 1998 J. Endocrinol. pmid:9795357
Horwood NJ et al. Osteotropic agents regulate the expression of osteoclast differentiation factor and osteoprotegerin in osteoblastic stromal cells. 1998 Endocrinology pmid:9794488
Hakeda Y et al. Osteoclastogenesis inhibitory factor (OCIF) directly inhibits bone-resorbing activity of isolated mature osteoclasts. 1998 Biochem. Biophys. Res. Commun. pmid:9790989
Hofbauer LC et al. Osteoprotegerin production by human osteoblast lineage cells is stimulated by vitamin D, bone morphogenetic protein-2, and cytokines. 1998 Biochem. Biophys. Res. Commun. pmid:9784422
Filvaroff E and Derynck R Bone remodelling: a signalling system for osteoclast regulation. 1998 Curr. Biol. pmid:9768352
Takai H et al. Transforming growth factor-beta stimulates the production of osteoprotegerin/osteoclastogenesis inhibitory factor by bone marrow stromal cells. 1998 J. Biol. Chem. pmid:9765225
Akatsu T et al. Osteoclastogenesis inhibitory factor suppresses osteoclast survival by interfering in the interaction of stromal cells with osteoclast. 1998 Biochem. Biophys. Res. Commun. pmid:9753612
Hofbauer LC and Heufelder AE Osteoprotegerin and its cognate ligand: a new paradigm of osteoclastogenesis. 1998 Eur. J. Endocrinol. pmid:9724069
Yamamoto M et al. Hypocalcemic effect of osteoclastogenesis inhibitory factor/osteoprotegerin in the thyroparathyroidectomized rat. 1998 Endocrinology pmid:9724059
Mizuno A et al. Structure of the mouse osteoclastogenesis inhibitory factor (OCIF) gene and its expression in embryogenesis. 1998 Gene pmid:9714833
Vidal ON et al. Osteoprotegerin mRNA is increased by interleukin-1 alpha in the human osteosarcoma cell line MG-63 and in human osteoblast-like cells. 1998 Biochem. Biophys. Res. Commun. pmid:9703989
Brändström H et al. Tumor necrosis factor-alpha and -beta upregulate the levels of osteoprotegerin mRNA in human osteosarcoma MG-63 cells. 1998 Biochem. Biophys. Res. Commun. pmid:9703945
Morinaga T et al. Cloning and characterization of the gene encoding human osteoprotegerin/osteoclastogenesis-inhibitory factor. 1998 Eur. J. Biochem. pmid:9688283
Kwon BS et al. TR1, a new member of the tumor necrosis factor receptor superfamily, induces fibroblast proliferation and inhibits osteoclastogenesis and bone resorption. 1998 FASEB J. pmid:9657524
Tsuda E and Higashio K [Osteoclastogenesis inhibitory factor (OCIF)/OPG]. 1998 Nippon Rinsho pmid:9648461
Mizuno A et al. Severe osteoporosis in mice lacking osteoclastogenesis inhibitory factor/osteoprotegerin. 1998 Biochem. Biophys. Res. Commun. pmid:9647741
Brändström H et al. Regulation of osteoprotegerin mRNA levels by prostaglandin E2 in human bone marrow stroma cells. 1998 Biochem. Biophys. Res. Commun. pmid:9642127
Tsukii K et al. Osteoclast differentiation factor mediates an essential signal for bone resorption induced by 1 alpha,25-dihydroxyvitamin D3, prostaglandin E2, or parathyroid hormone in the microenvironment of bone. 1998 Biochem. Biophys. Res. Commun. pmid:9610359
Emery JG et al. Osteoprotegerin is a receptor for the cytotoxic ligand TRAIL. 1998 J. Biol. Chem. pmid:9603945
Matsuzaki K et al. Osteoclast differentiation factor (ODF) induces osteoclast-like cell formation in human peripheral blood mononuclear cell cultures. 1998 Biochem. Biophys. Res. Commun. pmid:9600092
Bucay N et al. osteoprotegerin-deficient mice develop early onset osteoporosis and arterial calcification. 1998 Genes Dev. pmid:9573043
Tomoyasu A et al. Characterization of monomeric and homodimeric forms of osteoclastogenesis inhibitory factor. 1998 Biochem. Biophys. Res. Commun. pmid:9571159
Lacey DL et al. Osteoprotegerin ligand is a cytokine that regulates osteoclast differentiation and activation. 1998 Cell pmid:9568710
Yasuda H et al. Osteoclast differentiation factor is a ligand for osteoprotegerin/osteoclastogenesis-inhibitory factor and is identical to TRANCE/RANKL. 1998 Proc. Natl. Acad. Sci. U.S.A. pmid:9520411
Yasuda H et al. Identity of osteoclastogenesis inhibitory factor (OCIF) and osteoprotegerin (OPG): a mechanism by which OPG/OCIF inhibits osteoclastogenesis in vitro. 1998 Endocrinology pmid:9492069
Yamaguchi K et al. Characterization of structural domains of human osteoclastogenesis inhibitory factor. 1998 J. Biol. Chem. pmid:9478964
Miyamoto A et al. Establishment and characterization of an immortal macrophage-like cell line inducible to differentiate to osteoclasts. 1998 Biochem. Biophys. Res. Commun. pmid:9464281
Hofbauer LC and Heufelder AE Osteoprotegerin: a novel local player in bone metabolism. 1997 Eur. J. Endocrinol. pmid:9368500
Simonet WS et al. Osteoprotegerin: a novel secreted protein involved in the regulation of bone density. 1997 Cell pmid:9108485
pmid:29502401
Li N et al. Calycosin attenuates osteoporosis and regulates the expression of OPG/RANKL in ovariectomized rats MAPK signaling. 2016 Pharmazie pmid:29441931
pmid:29402836
pmid:29348072
pmid:29313442
pmid:29262817
pmid:29253005
pmid:29121799
pmid:29050490
pmid:29025654
pmid:28957555
Ozaki Y et al. Treatment of OPG-deficient mice with WP9QY, a RANKL-binding peptide, recovers alveolar bone loss by suppressing osteoclastogenesis and enhancing osteoblastogenesis. 2017 PLoS ONE pmid:28937990
Tschiderer L et al. Osteoprotegerin concentration and risk of cardiovascular outcomes in nine general population studies: Literature-based meta-analysis involving 26,442 participants. 2017 PLoS ONE pmid:28837646
Choi EM et al. Actein alleviates 2,3,7,8-tetrachlorodibenzo-p-dioxin-mediated cellular dysfunction in osteoblastic MC3T3-E1 cells. 2017 Environ. Toxicol. pmid:28836330
pmid:28814613
pmid:28805201
pmid:28774557
pmid:28772237
pmid:28758134
pmid:28742795
pmid:28739719
Chen X et al. Emodin suppresses cadmium-induced osteoporosis by inhibiting osteoclast formation. 2017 Environ. Toxicol. Pharmacol. pmid:28738286
Åšliwicka E et al. Serum irisin and myostatin levels after 2 weeks of high-altitude climbing. 2017 PLoS ONE pmid:28732027
pmid:28731198
pmid:28721974
pmid:28700003
pmid:28683789
pmid:28674791
pmid:28674790
pmid:28661441
pmid:28654984
pmid:28618255
pmid:28617323
pmid:28614819
Bergdolt S et al. Osteoblast-specific overexpression of complement receptor C5aR1 impairs fracture healing. 2017 PLoS ONE pmid:28614388
pmid:28605877
pmid:28593808
pmid:28577080
pmid:28576140
pmid:28567553
pmid:28556971
Middleton K et al. Microfluidic co-culture platform for investigating osteocyte-osteoclast signalling during fluid shear stress mechanostimulation. 2017 J Biomech pmid:28552413
pmid:28530511
pmid:28494644
Spirlandeli AL et al. Hepatic Osteodystrophy: The Mechanism of Bone Loss in Hepatocellular Disease and the Effects of Pamidronate Treatment. 2017 Clinics (Sao Paulo) pmid:28492723
pmid:28488158
pmid:28473060
pmid:28450653
pmid:28429221
pmid:28421466
pmid:28386999
pmid:28385082
pmid:28373003
pmid:28367895
pmid:28363435
pmid:28337794
pmid:28320782
Liu J et al. MicroRNA-32 promotes calcification in vascular smooth muscle cells: Implications as a novel marker for coronary artery calcification. 2017 PLoS ONE pmid:28319142
pmid:28318623
pmid:28303296
pmid:28302565
pmid:28290259
pmid:28285639
pmid:28263839
Songia P et al. Identification of Patients Affected by Mitral Valve Prolapse with Severe Regurgitation: A Multivariable Regression Model. 2017 Oxid Med Cell Longev pmid:28261377
pmid:28260080
Jia J et al. Estrogen stimulates osteoprotegerin expression via the suppression of miR-145 expression in MG-63 cells. 2017 Mol Med Rep pmid:28260003

Table of Content